Cargando…
Evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: A randomized, standard controlled clinical study
AIM OF THE STUDY: The aim of the following study is to evaluate the efficacy and tolerability of a compound Unani formulation in hyperlipidemia on clinical and biochemical parameters. MATERIALS AND METHODS: A total of 90 patients with total cholesterol level of 220 mg/dl and above were included. In...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4097930/ https://www.ncbi.nlm.nih.gov/pubmed/25035636 http://dx.doi.org/10.4103/0975-7406.130975 |
_version_ | 1782326254502936576 |
---|---|
author | Jahangir, Umar Khan, Asim Ali Kapoor, Prem Jalees, Farhan Urooj, Shaista |
author_facet | Jahangir, Umar Khan, Asim Ali Kapoor, Prem Jalees, Farhan Urooj, Shaista |
author_sort | Jahangir, Umar |
collection | PubMed |
description | AIM OF THE STUDY: The aim of the following study is to evaluate the efficacy and tolerability of a compound Unani formulation in hyperlipidemia on clinical and biochemical parameters. MATERIALS AND METHODS: A total of 90 patients with total cholesterol level of 220 mg/dl and above were included. In Group ‘A’ thirty patients with total cholesterol 243.5 ± 5.294 mg/dl received Unani formulation safoof-e-muhazzil (SM) in its classical powder form 5 g twice daily orally, in Group ‘B’ thirty patients with total cholesterol 234 ± 3.822 mg/dl received the SM but in compressed tablet form in the same dosage and in Group ‘C’ 30 patients with total cholesterol 242.7 ± 5.563 mg/dl received atorvastatin 10 mg as a standard control. Follow-up was carried out on second, fourth and 6th week and patients were evaluated on clinical as well as biochemical parameters. RESULTS: Group A before treatment had mean total cholesterol of 243.5 ± 5.294 mg/dl which decreased significantly after treatment to 225.6 ± 5.953 mg/dl (P < 0.001) with a percentage change of 7.35%. Group B had mean total cholesterol of 234 ± 3.822 mg/dl which was significantly reduced to 212.67 ± 3.94 mg/dl (P < 0.001) post-treatment with a percentage change of 9.11%. Control Group C having mean total cholesterol of 242.7 ± 5.563 mg/dl before treatment was significantly decreased to 178.73 ± 4.669 mg/dl (P < 0.001) post-treatment with a percentage change of 26.3%. Group A had significant relief 20.72% (P < 0.001) in fatigue, 16.09% (P > 0.5) relief in palpitation and 26.17% (P < 0.001) relief in dyspnea post-treatment. Group B fatigue decreased significantly by 18.14% (P < 0.01), palpitation by 22.91% (P < 0.01) and dyspnea by 20.46% (P < 0.01). In Group C a non-significant increase of 2.2% was observed in fatigue post-treatment, palpitation decreased by 10.22% non-significantly and dyspnea decreased significantly by 17.64% (P < 0.001). Results indicate that the test drug safely and effectively ameliorates the clinical condition of patients with hyperlipidemia while decreasing cholesterol level as well. |
format | Online Article Text |
id | pubmed-4097930 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-40979302014-07-17 Evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: A randomized, standard controlled clinical study Jahangir, Umar Khan, Asim Ali Kapoor, Prem Jalees, Farhan Urooj, Shaista J Pharm Bioallied Sci Original Article AIM OF THE STUDY: The aim of the following study is to evaluate the efficacy and tolerability of a compound Unani formulation in hyperlipidemia on clinical and biochemical parameters. MATERIALS AND METHODS: A total of 90 patients with total cholesterol level of 220 mg/dl and above were included. In Group ‘A’ thirty patients with total cholesterol 243.5 ± 5.294 mg/dl received Unani formulation safoof-e-muhazzil (SM) in its classical powder form 5 g twice daily orally, in Group ‘B’ thirty patients with total cholesterol 234 ± 3.822 mg/dl received the SM but in compressed tablet form in the same dosage and in Group ‘C’ 30 patients with total cholesterol 242.7 ± 5.563 mg/dl received atorvastatin 10 mg as a standard control. Follow-up was carried out on second, fourth and 6th week and patients were evaluated on clinical as well as biochemical parameters. RESULTS: Group A before treatment had mean total cholesterol of 243.5 ± 5.294 mg/dl which decreased significantly after treatment to 225.6 ± 5.953 mg/dl (P < 0.001) with a percentage change of 7.35%. Group B had mean total cholesterol of 234 ± 3.822 mg/dl which was significantly reduced to 212.67 ± 3.94 mg/dl (P < 0.001) post-treatment with a percentage change of 9.11%. Control Group C having mean total cholesterol of 242.7 ± 5.563 mg/dl before treatment was significantly decreased to 178.73 ± 4.669 mg/dl (P < 0.001) post-treatment with a percentage change of 26.3%. Group A had significant relief 20.72% (P < 0.001) in fatigue, 16.09% (P > 0.5) relief in palpitation and 26.17% (P < 0.001) relief in dyspnea post-treatment. Group B fatigue decreased significantly by 18.14% (P < 0.01), palpitation by 22.91% (P < 0.01) and dyspnea by 20.46% (P < 0.01). In Group C a non-significant increase of 2.2% was observed in fatigue post-treatment, palpitation decreased by 10.22% non-significantly and dyspnea decreased significantly by 17.64% (P < 0.001). Results indicate that the test drug safely and effectively ameliorates the clinical condition of patients with hyperlipidemia while decreasing cholesterol level as well. Medknow Publications & Media Pvt Ltd 2014 /pmc/articles/PMC4097930/ /pubmed/25035636 http://dx.doi.org/10.4103/0975-7406.130975 Text en Copyright: © Journal of Pharmacy and Bioallied Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Jahangir, Umar Khan, Asim Ali Kapoor, Prem Jalees, Farhan Urooj, Shaista Evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: A randomized, standard controlled clinical study |
title | Evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: A randomized, standard controlled clinical study |
title_full | Evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: A randomized, standard controlled clinical study |
title_fullStr | Evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: A randomized, standard controlled clinical study |
title_full_unstemmed | Evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: A randomized, standard controlled clinical study |
title_short | Evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: A randomized, standard controlled clinical study |
title_sort | evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: a randomized, standard controlled clinical study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4097930/ https://www.ncbi.nlm.nih.gov/pubmed/25035636 http://dx.doi.org/10.4103/0975-7406.130975 |
work_keys_str_mv | AT jahangirumar evaluationofaclassicalunanipharmacopeialformulationsafoofemuhazzilinhyperlipidemiaarandomizedstandardcontrolledclinicalstudy AT khanasimali evaluationofaclassicalunanipharmacopeialformulationsafoofemuhazzilinhyperlipidemiaarandomizedstandardcontrolledclinicalstudy AT kapoorprem evaluationofaclassicalunanipharmacopeialformulationsafoofemuhazzilinhyperlipidemiaarandomizedstandardcontrolledclinicalstudy AT jaleesfarhan evaluationofaclassicalunanipharmacopeialformulationsafoofemuhazzilinhyperlipidemiaarandomizedstandardcontrolledclinicalstudy AT uroojshaista evaluationofaclassicalunanipharmacopeialformulationsafoofemuhazzilinhyperlipidemiaarandomizedstandardcontrolledclinicalstudy |